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The hPrp19–CDC5L complex plays a crucial role during
human pre-mRNA splicing by catalytic activation of the
spliceosome. In order to elucidate the molecular architecture
of the hPrp19–CDC5L complex, the crystal structure of
CTNNBL1, one of the major components of this complex, was
determined. Unlike canonical ARM-repeat proteins such as
-catenin and importin-, CTNNBL1 was found to contain a
twisted and extended ARM-repeat structure at the C-terminal
domain and, more importantly, the protein formed a stable
dimer. A highly negatively charged patch formed in the
N-terminal ARM-repeat domain of CTNNBL1 provides a
binding site for CDC5L, a binding partner of the protein in
the hPrp19–CDC5L complex, and these two proteins form a
complex with a stoichiometry of 2:2. These findings not only
present the crystal structure of a novel ARM-repeat protein,
CTNNBL1, but also provide insights into the detailed
molecular architecture of the hPrp19–CDC5L complex.
Received 29 August 2013





Pre-mRNA splicing is a modification of the nascent pre-
mRNA transcript in which introns are removed and exons
are joined, and is catalyzed by the spliceosome, a dynamic
megadalton-sized complex composed of four ribonucleo-
protein particles (snRNPs; U1, U2, U5 and U4/U6) and non-
snRNP proteins such as the hPrp19–CDC5L complex (Wahl
et al., 2009; Staley & Guthrie, 1998; Makarov et al., 2002).
snRNPs are formed by snRNAs, along with their associated
proteins, and bind to specific sequences on the pre-mRNA
substrate (Guo et al., 2009). snRNPs and non-snRNP proteins
assemble to form the spliceosome in consecutive order and in
a highly dynamic procedure (Wahl et al., 2009; Kra¨mer, 1996;
Murray & Jarrell, 1999). The first recognition of pre-mRNA
involves binding of the U1 snRNP to the 50 splice site, followed
by binding of the U2 snRNP to the branch-point sequence
(BPS), forming the prespliceosome or complex A (Will &
Lu¨hrmann, 1997). The U4/U6–U5 tri-snRNP is then recruited
to the assembling spliceosome to form complex B. Following
dramatic compositional and structural rearrangements of
complex B, the first transesterification reaction occurs and
generates complex C, which then catalyzes the second splicing
reaction. After completion of catalysis, the postspliceosomal
complex is disassembled and the mRNA and U2, U5 and U6
snRNPs are released for reuse in subsequent splicing reactions.
In addition to the snRNPs, various non-snRNP proteins are
also involved in the formation of the spliceosome, and many of
them are known to play crucial roles in the splicing reaction.
One well known non-snRNP protein complex is the hPrp19–
CDC5L complex in humans, which is referred to as the NTC
(nineteen complex) in yeast (Tarn et al., 1993, 1994). The
hPrp19 protein, which is a major component of the hPrp19–
CDC5L complex, is known to be a highly conserved splicing
factor required for the activation of the spliceosome, and
exhibits E3 ubiquitin ligase activity in vitro (Hatakeyama et al.,
2001; Ohi et al., 2003; Chan et al., 2003; Ohi & Gould, 2002).
The hPrp19–CDC5L complex consists of seven proteins:
hPrp19, CDC5L, PRL1, AD002, SPF27, CTNNBL1 and
HSP73 (Makarova et al., 2004). While homologues of four
proteins of the hPrp19–CDC5L complex, hPrp19, CDC5L,
PRL1 and SPF27, are found in the yeast NTC, homologues of
CTNNBL1, HSP73 and AD002 are absent in the yeast NTC
(Chen et al., 2002; Ohi & Gould, 2002; Tarn et al., 1994).
Human CTNNBL1 (catenin--like 1), a component of the
hPrp19–CDC5L complex, has been identified as a widely
expressed nuclear protein that is expressed in multiple human
tissues (Jabbour et al., 2003) and is conserved in a variety of
vertebrates. Studies of the molecular architecture of the
hPrp19–CDC5L complex have shown that CTNNBL1 inter-
acts with CDC5L and AD002 in order to form a complex. The
limited proteolysis of the purified hPrp19–CDC5L complex
also suggests that the CTNNBL1–AD002 heterooligomer
binds the hPrp19–CDC5L complex core via the N-terminal
domain of CDC5L (Grote et al., 2010). Recently, it was proven
that the hPrp19–CDC5L complex is formed by the interaction
of CTNNBL1 with CDC5L and Prp31; in particular, NLS3
located in the N-terminal domain of CDC5L is crucially
involved in the binding to CTNNBL1 (Ganesh et al., 2011).
Interestingly, it has been reported that CTNNBL1 also
interacts with activation-induced deaminase (AID), suggesting
the involvement of CTNNBL1 in antibody diversity (Conti-
cello et al., 2008). This interaction suggests that the nuclear
localization signal motif directs AID to the nucleoli, where
it colocalizes with CTNNBL1 and physically associates with
nucleolin and nucleophosmin (Hu et al., 2013). More
interestingly, a deficiency of the spliceosome-associated factor
CTNNBL1 results in embryonic lethality in mice (Chandra et
al., 2013). In addition, a genome-wide survey and a functional
brain-imaging study have identified CTNNBL1 as a memory-
related protein (Papassotiropoulos et al., 2013).
Recently, a crystal structure of CTNNBL1 was reported,
showing a monomeric structure (Huang et al., 2013). Here, we
determined the dimeric structure of CTNNBL1 and found that
the protein exhibits a novel ARM-repeat structure compared
with the canonical ARM-repeat proteins such as -catenin
and importin-. Based on the dimeric structure of CTNNBL1,
we identified the CDC5L binding site of the protein and
revealed that the CTNNBL1–CDC5L complex is formed with
a 2:2 stoichiometry. Our findings therefore provide new
insights into the molecular architecture of the hPrp19–CDC5L
complex.
2. Materials and methods
2.1. Protein production
The gene coding for human CTNNBL1 (residues 77–563)
was amplified by polymerase chain reaction (PCR) from the
human cDNA library, and the amplified fragment was digested
with NdeI and SalI restriction enzymes and ligated into a
modified VHb fusion vector (pPosKJ) which contained a
6His tag and bacterial haemoglobin at the N-terminus of the
target protein (Kwon et al., 2005). In order to obtain mutant
CTNNBL1 proteins, site-directed mutagenesis was performed
using PfuTurbo DNA polymerase (Stratagene). All oligo-
nucleotides used in the study were purchased in a salt-free
grade from Bioneer (Daejeon, Republic of Korea) and are
summarized in the Supporting Information1. The resulting
plasmid pPosKJ:CTNNBL1 was transformed into Escherichia
coli strain B834(DE3) and was grown to an OD600 of 0.6 in
LB medium containing 100 mg l1 ampicillin at 310 K. After
induction with 1.0 mM IPTG, the cells were grown for a
further 20 h at 295 K. The cultured cells were harvested by
centrifugation at 5000g for 20 min at 277 K, and the cell pellet
was resuspended in ice-cold buffer A (50 mM Tris–HCl pH
8.0) containing 10 mM imidazole and disrupted by ultra-
sonication. The cell debris was removed by centrifugation at
11 000g for 1 h and the lysate was bound to Ni–NTA agarose
(Qiagen). After washing with buffer A containing 20 mM
imidazole, the bound proteins were eluted with 300 mM
imidazole in buffer A. The 6His tag and VHb were then
removed by treatment with TEV protease (Invitrogen) and
Ni–NTA chromatography. Trace amount of contaminants
were removed by applying ion-exchange and size-exclusion
chromatography (Superdex 200, GE Healthcare). The purified
protein was concentrated to approximately 35 mg l1 in
40 mM Tris–HCl pH 8.0 and stored at 193 K for crystallization
trials. SDS–PAGE analysis of the purified protein showed a
single band corresponding to the calculated molecular weight
of the target protein. SeMet-substituted CTNNBL1 and the
mutant proteins were prepared similarly to the wild-type
CTNNBL1. For the production of CDC5L141–377, the gene
coding for CDC5L141–377 was cloned into pET-30a expression
vector and the CDC5L141–377 protein with a 6His tag at the
C-terminus was purified similarly to CTNNBL1 but without
TEV protease treatment.
2.2. Crystallization, data collection and structure
determination
The initial crystallization conditions were obtained by
sparse-matrix screening. Crystals suitable for diffraction
appeared using 100 mM CAPS pH 9.5, 8% PEG 8K, 0.2 M
NaCl at 295 K within 2 d and reached their maximal size in
about 7 d, with dimensions of approximately 0.2  0.1 
0.1 mm. For data collection, 30%(v/v) glycerol was added to
the crystallizing precipitant as a cryoprotectant and the crys-
tals were immediately placed in a 100 K nitrogen-gas stream.
X-ray diffraction data were collected from native crystals to a
resolution of 2.7 A˚ on beamline 7A of the Pohang Accelerator
Laboratory (PAL; Republic of Korea) using a Quantum 270
CCD detector (San Diego, California, USA). The data were
then indexed, integrated and scaled using the HKL-2000 suite
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1 Supporting information has been deposited in the IUCr electronic archive
(Reference: WA5060).
(Otwinowski & Minor, 1997). The crystals belonged to space
group P3121, with unit-cell parameters a = b = 90, c = 178 A˚,
 = 120. With one CTNNBL1 molecule in the asymmetric
unit, the crystal volume per unit of protein weight was
3.74 A˚3 Da1, corresponding to a solvent content of 67.1%
(Matthews, 1968). SeMet-substituted protein crystals were
obtained using the same crystallization condition as used
for the native protein crystal. Single-wavelength anomalous
dispersion (SAD) data were collected from an SeMet protein
crystal on beamline 7A at PAL to a wavelength of 0.97953 A˚.
14 Se atoms out of the expected 17 in the asymmetric unit
were identified at 3.2 A˚ resolution using SOLVE (Terwilliger
& Berendzen, 1999). The electron density was improved by
density modification using RESOLVE (Terwilliger, 2000),
resulting in 52% of the cloned residues being automatically
built. Further model building was performed manually using
WinCoot (Emsley & Cowtan, 2004), and refinement was
performed with REFMAC5 (Murshudov et al., 2011) in CCP4
(Winn et al., 2011) and CNS (Bru¨nger et al., 1998) (Supple-
mentary Fig. S3). The data statistics are summarized in Table 1.
Refined models of human CTNNBL1 consisting of residues
77–563 and residues 33–563 have been deposited in the
Protein Data Bank as entries 4mfu and 4mfv, respectively.
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Table 1
Data-collection, phasing and refinement statics for human CTNNBL1.








Space group P3121 P31 P3121
Unit-cell parameters
a (A˚) 90.15 90.04 90.03
b (A˚) 90.15 90.04 90.03
c (A˚) 178.56 175.75 175.74
 =  () 90.00 90.00 90.00







Rmerge (%) 9.5 (32.8) 7.8 (26.6) 9.1 (80.7)
hI/(I)i 36.9 (2.2) 30.3 (2.6) 41.8 (3.2)
Completeness (%) 95.8 (71.5) 94.1 (77.6) 100.0 (100.0)
Multiplicity 13.9 (4.7) 7.2 (3.1) 10.1 (9.8)
Refinement
Resolution (A˚) 50.00–2.74 50.00–2.92
No. of reflections 20631 30828
Rwork/Rfree (%) 24.7/31.9 23.3/30.5
No. of protein atoms 3917 7818
Overall B factor (A˚2) 89.03 92.29
R.m.s. deviations
Bond lengths (A˚) 0.019 0.019
Bond angles () 1.426 1.481
Figure 1
Crystal structure of human CTNNBL1. (a) Domain identification of CTNNBL1. The NLS and EDR regions represent the nuclear localization sequence
and the glutamate/aspartate-rich region, respectively, and are labelled appropriately. The NAR and CAR domains represent the N-terminal and
C-terminal ARM-repeat domains, respectively. (b) The monomeric structure of CTNNBL1. The secondary-structure elements are shown as cylindrical
cartoon representations. The H1, H2 and H3 helices of each ARM repeat are distinguished by green, red and yellow colours, respectively, and the
N-terminal capping region and the eight ARM repeats are labelled. The CDC5L binding site and the dimerization interface are indicated by dotted
rectangles and are labelled appropriately. A schematic diagram of the ARM-repeat arrangement of CTNNBL1 is presented (right), and the NAR and
CAR domains are labelled.
2.3. In vitro pull-down assay
In order to identify the CDC5L binding site of CTNNBL1,
a pull-down assay was performed. For binding to the Ni–NTA
column, the CDC5L141–377 protein was purified with a 6His
tag at the C-terminus and CTNNBL1 was purified as the
native protein. The wild type and various mutants of
CTNNBL1 were mixed with the CDC5L141–377 protein and
incubated at 277 K for 2 h. The mixture was loaded onto an
Ni–NTA column and washed thoroughly with 10 mM imida-
zole to avoid nonspecific binding of CTNNBL1 to the Ni–NTA
resin. The sample was eluted with 300 mM imidazole and run
on SDS–PAGE.
2.4. Size-exclusion chromatographic analysis
In order to confirm the dimerization of CTNNBL1 and to
measure the molecular weight of the protein, 500 ml 2 mg l1
CTNNBL1 was injected onto a Superdex 200 10/300 column
(GE Healthcare) at a flow rate of 0.5 ml min1 at various
concentrations of NaCl: 0, 100, 150, 200, 250 and 300 mM. The
molecular weights of the eluted samples were calculated based
on the calibration curve of standard samples. The molecular
weight of the CTNNBL1–CDC5L141–377 complex was deter-
mined using a procedure similar to that used for CTNNBL1.
2.5. Multi-angle light-scattering analysis (MALS)
The molecular weight and dimerization state of CTNNBL1
were monitored by size-exclusion chromatography multi-
angle light scattering (SEC-MALS). The purified CTNNBL1
was injected onto a Superdex 200 HR 10/30 gel-filtration
column (GE Healthcare) equilibrated with 20 mM Tris pH 8.0
containing 0, 100, 200, 300 and 400 mM NaCl. The chroma-
tography system was coupled to a three-angle light-scattering
detector (mini-DAWN TREOS) and a refractive-index
detector (Optilab DSP) (Wyatt). Data were collected at a flow
rate of 0.4 ml min1. Data acquisition and processing was
carried out using the ASTRA software (Wyatt).
3. Results and discussion
3.1. CTNNBL1 is a novel ARM-repeat protein
To study the structural features of human CTNNBL1 and
the molecular architecture of the hPrp19–CDC5L complex,
we determined the crystal structure of an N-terminally trun-
cated form of human CTNNBL1 (amino-acid residues 77–
563). The truncated N-terminal region consisted of the nucleus
localization sequence (NLS; amino-acid residues 1–33) and
the glutamate/aspartate-rich region (EDR region; amino-acid
residues 34–76) (Fig. 1a and Supplementary Fig. S1). The
crystal belonged to space group P3121, and one polypeptide
was present in the asymmetric unit of the structure. The crystal
structure of CTNNBL1 showed that the protein consists
mainly of -helices and forms an armadillo (ARM) repeat
structure (Fig. 1b). The first two helices located in the
N-terminal region of the structure showed a HEAT-repeat-
like structure and formed an N-terminal capping region. The
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Figure 2
Extended and twisted ARM-repeat structures of the CAR domain. (a) Twist angles and lengths of the H2 helices of ARMs VI, VII and VIII. The H2
helices of the CTNNBL1 structure are shown as a cylindrical cartoon representation. Twist angles are measured based on the H2 helices. The twist angles
and lengths of the H2 helices of ARMs VI, VII and VIII are indicated. (b) Comparison of the structure of CTNNBL1 with other canonical ARM-repeat
proteins: -catenin and importin-. The structures of CTNNBL1, -catenin and importin- are shown as cylindrical cartoon representations in the same
orientation. The NAR and CAR domains are distinguished by cyan and red colours, respectively, and are labelled appropriately. The NAR and CAR
domain portions of -catenin and importin- are distinguished using the same colour scheme as for CTNNBL1.
rest of the helices constituted eight ARM repeats and, as
observed in ARM-repeat proteins such as -catenin and
importin-, each ARM in CTNNBL1 is composed of three
helices (H1, H2 and H3). The H2 and H3 helices are packed
antiparallel to each other and the H1 helix is perpendicular to
them (Fig. 1).
However, the CTNNBL1 structure showed that the protein
contains unique ARM-repeat structures in the C-terminal
region of the protein. The N-terminal capping region and
the first six ARM repeats (ARM I–ARM VI) of CTNNBL1
showed a canonical ARM-repeat structure that superposed
well with the structures of other ARM-repeat proteins such
as -catenin and importin-. Interestingly, the last two ARM
repeats (ARM VII and ARM VIII) of the protein exhibited
unique structural conformations (Fig. 2). In canonical ARM-
repeat structures each repeat is related to its neighbour by a
right-handed rotation of 30 about an axis that is approxi-
mately parallel to the superhelix axis. In CTNNBL1, the
rotation angles of each ARM from the N-terminal capping
region to ARM VI were similar to those in -catenin and
importin-, that is 30 on an average. However, ARM VII and
ARM VIII of CTNNBL1 are extremely twisted, with angles of
50 and 70, respectively (Fig. 2a). Another interesting struc-
tural feature of CTNNBL1 is the extended H2 and H3 helices
of ARM VII. The length of the ARM VII H2 helix is twice
that of the other helices, and H3 is separated into two tandem
helices (H3 and H30) (Fig. 2). As a result of these unique
structural features of ARM VII and ARM VIII of CTNNBL1,
we divided the protein into two distinct domains: an N-term-
inal canonical ARM-repeat (NAR) domain and a C-terminal
extended and twisted ARM-repeat (CAR) domain. In fact,
the unique structural conformation of the CAR domain
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Figure 3
Dimerization of CTNNBL1. (a) Structure of the CTNNBL1 dimer. The structure of the CTNNBL1 dimer is shown as a cylindrical cartoon
representation. The NAR and CAR domains of molecules A and B are distinguished in cyan and red and in magenta and orange, respectively, and are
labelled appropriately. (b) Size-exclusion chromatographic analysis. Dimer formation of CTNNBL1 was analyzed by the addition of various
concentrations of NaCl. The elution peaks corresponding to the dimeric and monomeric forms of CTNNBL1 are indicated by arrows, and the
concentrations of NaCl added to the protein solution are shown in parentheses. Dimeric and monomeric CTNNBL1 eluted at molecular weights of 110
and 60 kDa, respectively. For precise analysis of the molecular weight, standard samples of thyroglobulin (669 kDa), ferritin (440 kDa), aldolase
(158 kDa), conalbumin (75 kDa), ovalbumin (44 kDa) and carbonic anhydrase (29 kDa) were used for calibration of the size-exclusion chromatography
and are labelled 1–6, respectively. (c) SEC-MALS analysis of CTNNBL1 with various concentrations of NaCl. Molecular mass and refractive index are
plotted as a function of elution volume. Peaks for dimers and monomers are indicated by arrows. (d) The dimerization interface of CTNNBL1. The
structure of CTNNBL1 is presented as an electrostatic potential model, and the secondary-structure elements involved in the dimerization of the protein
are shown as a cylindrical cartoon representation and labelled appropriately.
positioned these two domains in sufficient proximity to form a
hydrogen bond between Asp274 from ARM IV and Glu544
from ARM VIII.
3.2. CTNNBL1 forms a stable dimer
To date, all ARM-repeat proteins have been reported to
function as monomers. However, the crystallographic P3121
symmetry of CTNNBL1 unexpectedly showed that the protein
forms a dimer, even though a monomeric protein was present
in the asymmetric unit of our structure (Fig. 3a). The dimeric
state of CTNNBL1 was further verified by size-exclusion
chromatography, which showed a molecular weight of
110 kDa, similar to the calculated molecular weight for the
CTNNBL1 dimer (Fig. 3b). Interestingly, the N-terminal
capping region and the first four ARM repeats (ARM I, ARM
II, ARM III and ARM III) participated in the dimerization of
CTNNBL1, even though, as described above, these repeats are
structurally quite similar to those of canonical ARM-repeat
proteins. The N-terminal capping region and the first four
ARM repeats from one polypeptide contacted the corre-
sponding repeats from another polypeptide, and because of
the rotation of the ARM repeats the contact modes of each
repeat were quite different from each other (Figs. 3a and 3d).
The H2 helices of the N-terminal capping region and ARM I
formed antiparallel helix dimers between the H2 helices of
each monomer and seem to play a major role in CTNNBL1
dimerization. The connecting loops of H1 and H2 of each
ARM repeat were involved in the contacts of ARM II and
ARM II and of ARM III and ARM III. The contact between
two ARM IV repeats was constituted by the formation of an
antiparallel helix dimer between the H1 helices of each ARM
IV. Detailed observation of the
CTNNBL1 structure showed that
dimerization of the protein was
mediated by combinations of
hydrophobic and hydrophilic
interactions between two mono-
mers. Several hydrophobic resi-
dues in the N-terminal capping
region, ARM I, ARM II and
ARM III were involved in
hydrophobic interactions: Ile86,
Leu87 and Ile101 from the
N-terminal capping region,
Leu147, Gly148 and Gly151 from
ARM I, Val183, Ala187, Gly191
and Leu196 from ARM II and
Gly236 from ARM III. These
hydrophobic interactions do not
seem to provide sufficient force to
form a dimer, and many hydro-
philic residues assist the dimer-
ization of the protein by the
formation of hydrogen bonds to
hydrophilic residues from the
partner polypeptide (Fig. 3d). 29
amino acids are involved in
dimerization in each monomer,
and 963.3 and 963.7 A˚2 of
solvent-accessible surface area is
buried per monomer, corre-
sponding to 3.8% of the total
surface area of each monomer.
In order to confirm the dimer-
ization of the CTNNBL1 protein
and the involvement of hydro-
philic interactions in the dimer-
ization contacts, we tested how
the addition of NaCl affected the
dimerization state of the protein.
When size-exclusion chromato-
graphy was performed using
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Figure 4
Interaction between CTNNBL1 and CDC5L. (a) CDC5L binding site of CTNNBL1. The structure of
CTNNBL1 is presented as an electrostatic potential model and the CDC5L binding site is indicated by a
dotted rectangle (left). The CDC5L binding site of CTNNBL1 is shown as a cylindrical cartoon
representation (right). The negatively charged residues located in the H3 helices of the NAR domain are
presented as stick models in cyan and are labelled. Residues whose simultaneous mutation abolishes the
binding to CDC5L are distinguished in green. (b) CTNNBL1–CDC5L141–377 pull-down assay. Recombinant
CTNNBL1 protein without a 6His tag was mixed with CDC5L141–377 protein with a 6His tag at the
C-terminus and Ni–NTA chromatography was performed. The eluted proteins were run on SDS–PAGE.
Each mutation of CTNNBL1 is labelled at the top of the figure. The molecular weights of the standard size
markers are labelled on the left side of the figure in kDa, and the CTNNBL1 and CDC5L141–377 proteins are
indicated by arrows on the right side of the figure and are labelled.
protein solutions with various concentrations of NaCl (0, 100,
150, 200, 250 and 300 mM), the CTNNBL1 protein still eluted
as a stable dimer at NaCl concentrations of up to 200 mM. The
dimerization of the protein started to break up on addition of
250 mM NaCl, and the protein was completely separated into
monomers by the addition of 300 mM NaCl (Fig. 3b). The
successful crystallization of CTNNBL1 as a dimer from a
crystallization condition that contained 200 mM NaCl further
confirmed that the protein forms a stable dimer when NaCl is
used at a concentration of at least 200 mM. The dimerization
of CTNNBL1 (amino-acid residues 77–563) was further
confirmed using size-exclusion chromatography multi-angle
light-scattering (SEC-MALS). CTNNBL1 protein eluted with
buffer containing 0, 100 or 200 mM NaCl showed a molecular
weight of 115 kDa, which corresponds to the dimeric state of
the protein. The protein eluted with buffer containing 300 or
400 mM NaCl eluted with a molecular weight of 58 kDa,
which corresponds to the monomeric state of the protein
(Fig. 3c). We also performed SEC-MALS analysis with NLS-
deleted full-length CTNNBL1 (amino-acid residues 33–365),
and the results showed that the full-length CTNNBL1 protein
forms a dimer in buffer containing 0, 100 or 200 mM NaCl and
is separated into monomers in buffer containing 300 or
400 mM NaCl (data not shown). Because the cellular salt
concentration is known to be lower than 200 mM, we suggest
that the CTNNBL1 protein also functions as a dimer in vivo. A
search for related crystal structures in the Protein Data Bank
showed that all ARM-repeat proteins exist as monomers, and
CTNNBL1 is therefore to our knowledge the first ARM-
repeat protein that functions as a dimer. Considering that
CTNNBL1 is a component of the hPrp19–CDC5L complex,
the dimerization of the protein might provide important
structural insights into the molecular architecture of the
hPrp19–CDC5L complex, which will be described later.
3.3. CDC5L binds to the negatively charged patch of
CTNNBL1
CDC5L binds CTNNBL1 in order to form the hPrp19–
CDC5L complex. It has also been reported that CDC5L
contains four highly positively charged NLS regions that are
involved in binding to CTNNBL1 (Ganesh et al., 2011).
Interestingly, our CTNNBL1 structure showed that the
protein forms a highly negatively charged patch at a position
similar to the NLS recognition site of importin- (Fig. 4a and
Supplementary Fig. S2). The negatively charged patch of
CTNNBL1 was formed mainly by glutamate and aspartate
residues located in the H3 helices of ARM I, ARM II, ARM
III and ARM IV (Fig. 4). The highly negatively charged patch
formed in the N-terminal canonical ARM-repeat region led us
to speculate that binding between CTNNBL1 and CDC5L
might be mediated by charge–charge interactions, as are
generally found when importin- binds to its NLS binding
partner.
In order to identify the binding mode between CTNNBL1
and CDC5L, we generated various CTNNBL1 mutants by
replacing glutamate and/or aspartate residues with arginines
and studied how the charge-replaced mutants affected the
formation of the CTNNBL1–CDC5L complex. Firstly, we
generated six single or double CTNNBL1 mutants (E167R,
E178R/E179R, D213R, D256R, E308R and E402R) and
performed pull-down assays using the mutants and recombi-
nant CDC5L protein containing four NLS regions
(CDC5L141–377; residues 141–377). Our results showed that
compared with wild-type CTNNBL1, the five single-point
CTNNBL1 mutations (E167R, D213R, D256R, E308R and
E402R) did not noticeably affect formation of the CTNNBL1–
CDC5L141–377 complex, while the E178R/E179R mutation
decreased complex formation by approximately 50%, indi-
cating that the binding surface between CTNNBL1 and
CDC5L141–377 is extensive (Fig. 4b). We then selected addi-
tional negatively charged residues such as Glu223, Glu264
and Asp315 and generated double-point CTNNBL1 mutants
(E223R/E264R, E223R/E308R, E223R/D315R, E264R/
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Figure 5
Stoichiometry of the CTNNBL1–CDC5L141–377 complex. (a) Size-
exclusion chromatography of the CTNNBL1–CDC5L141–377 complex
and comparison with that of the CTNNBL1 dimer. The eluted proteins at
the peak were run on SDS–PAGE. The same standard samples were used
as shown in Fig. 3(b) and are labelled in kDa. For precise analysis of
the molecular weight, the size-exclusion column was calibrated using
the standard samples. (b) The band intensity was analyzed using
GelQuant.NET (BiochemLabSolutions.com) and those of each protein
were measured using the SDS–PAGE of the CTNNBL1–CDC5L141–377
complex presented in (a).
E308R, E264/D315R and E308R/D315R). Interestingly, there
was a dramatic decrease in complex formation when the
E264R/E308R and E308R/D315R mutants were used.
Because the three residues Glu264, Glu308 and Asp315 are
located in the central regions of the H3 helices of ARM III
and ARM IV, we speculated that the CDC5L binding surface
of CTNNBL1 is formed by the negatively charged residues
located in the H3 helices of the canonical ARM repeats
(Fig. 4a). To further confirm the requirement of the H3 helices
for binding to CDC5L, we generated a five-point CTNNBL1
mutant (E178R/E179R/E264/E308/D315) and performed a
pull-down assay with the CDC5L141–377 protein. As expected,
complex formation between the CTNNBL1 mutant and
CDC5L141–377 was completely abolished, confirming that the
highly negatively charged patch formed by the acidic residues
in the H3 helices of the canonical ARM repeats recognizes the
highly positively charged NLS of CDC5L (Fig. 4b). Based on
these results, we conclude that although CTNNBL1 has a
completely different function to importin-, the protein
mimics the NLS recognition mode of importin- for its
interaction with CDC5L by using the novel ARM-repeat
structure.
3.4. CTNNBL1 binds CDC5L with a 2:2 stoichiometry
The dimerization of CTNNBL1 and the formation of its
complex with CDC5L raise the question of the stoichiometry
of the CTNNBL1–CDC5L complex, which might provide
important information on the molecular architecture of the
hPrp19–CDC5L complex. Firstly, we performed size-exclusion
chromatography to analyze the molecular weight of the
CTNNBL1–CDC5L141–377 complex, and the complex eluted at
a molecular weight of 150 kDa (Fig. 5a). Considering that
the molecular weight of the CDC5L141–377 monomer is 27 kDa,
this result indicates that the molecular weight of the eluted
CTNNBL1–CDC5L141–377 complex is smaller than the calcu-
lated molecular weight of a complex with a 2:2 CTNNBL1:
CDC5L stoichiometry (164 kDa), but is larger than that of a
complex with a 2:1 stoichiometry (137 kDa). Here, we need
to note that CDC5L141–377 bound to CTNNBL1 might be
located inside the groove formed between the NAR and the
CAR domains of CTNNBL1 (Fig. 4a), which might lead
to a smaller molecular weight of the eluted CTNNBL1–
CDC5L141–377 complex than the calculated molecular weight,
and we suspect that CTNNBL1 and CDC5L might form a
complex with 2:2 stoichiometry. We then quantified the band
intensities on SDS–PAGE using the eluted complex from
size-exclusion chromatography, and the stoichiometry of
CTNNBL1:CDC5L141–377 was calculated to be close to 1:1
(Fig. 5b). Considering that CTNNBL1 exists as a dimer, the
result indicates that a CTNNBL1 dimer binds two molecules
of CDC5L141–377 with a 2:2 stoichiometry. It has been reported
that CDC5L forms a homodimer in vivo and in vitro (Gra¨ub
et al., 2008; Grote et al., 2010), and size-exclusion chromato-
graphy using CDC5L141–377 also supported dimerization of the
protein. Taken together, we suggest that one CTNNBL1 dimer
might interact with one CDC5L141–377 dimer for formation of
the CTNNBL1–CDC5L141–377 complex.
4. Conclusion
The crystal structure of CTNNBL1 showed that the protein
has a novel type of ARM-repeat structure with two distinct
properties. Firstly, although the NAR domain contains a
canonical ARM-repeat structure similar to those found in
other reported ARM-repeat structures such as -catenin and
importin-, the CAR domain shows an extended and twisted
ARM-repeat structure. The unique structural features of the
CAR domain cause positioning of the domain proximal to the
NAR domain. Secondly, the protein forms a stable dimer; a
similar structure has not been reported to date among known
ARM-repeat proteins. These structural differences might be
explained by the functional difference between CTNNBL1
and other canonical ARM-repeat proteins. As a component of
the hPrp19–CDC5L complex, CTNNBL1 seems to adapt the
canonical ARM-repeat structure in the N-terminal domain
and to form a negatively charged patch for its interaction with
CDC5L. Interestingly, the CAR domain does not have a
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Figure 6
Schematic diagram of the molecular architecture of the hPrp19–CDC5L
complex. The identified domains of each of the components of the
hPrp19–CDC5L complex are distinguished with different colours and are
labelled appropriately. The CTNNBL1 dimer is shown as a cylindrical
cartoon representation and the other components of the complex are
shown as diagrams. The diagram reflects the dimerization of CTNNBL1
and its interaction with the N-terminal domain of CDC5L with a 2:2
stoichiometry.
negatively charged patch like the NAR domain, but rather
shows a broad positively charged surface, which is consistent
with the fact that this domain is not involved in interaction
with CDC5L. Although we were unable to define the role of
the CAR domain from our study, we speculated that this
domain might be involved in interaction with other compo-
nents of the hPrp19–CDC5L complex. The glutamate/
aspartate-rich region (EDR region; amino-acid residues 34–
76) might provide another binding site for other components
of the hPrp19–CDC5L complex. In order to examine the
structural features of the EDR region and its interaction with
the ARM-repeat structure of CTNNBL1, we also crystallized
and determined the structure of NLS-deleted full-length
CTNNBL1 (amino-acid residues 33–365). Our results showed
no electron-density map for the EDR region (data not shown),
indicating that the EDR region does not interact with the
ARM-repeat structure but rather interacts with other proteins
in the hPrp19–CDC5L complex such as AD002 and HSP73.
Recent studies of the molecular architecture of the hPrp19–
CDC5L complex using various methods such as electron
microscopy, analytical ultracentrifugation, co-immunopreci-
pitation and mass spectrophotometry have shown that (i)
human Prp19 forms a tetramer (Grote et al., 2010; Ohi et al.,
2005; Vander Kooi et al., 2010; Gra¨ub et al., 2008), (ii) human
CDC5L forms a homodimer both in vivo and in vitro (Grote et
al., 2010; Gra¨ub et al., 2008) and (iii) human Prp19 interacts
with the C-terminal domain of CDC5L with a 4:2 stoichio-
metry (Smits et al., 2013; Schmidt et al., 2010). Our crystallo-
graphic and stoichiometric studies showed that CTNNBL1
forms a dimer and interacts with the N-terminal NLS of
CDC5L with a 2:2 stoichiometry. Taken together, we propose
that CTNNBL1, CDC5L and Prp19 form a complex with a
2:2:4 stoichiometry and, combined with the relative sizes of the
proteins, we present a more detailed schematic diagram of the
hPrp19–CDC5L complex (Fig. 6). Further structural studies
of the individual components of the hPrp19–CDC5L complex
and their complexes are needed to obtain a more detailed
molecular architecture as well as the cellular function of the
complex.
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